Figure 2 from Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer

Potent therapeutic effects of 7 × 19 CAR-T in the preestablished solid tumor model of human glioblastoma. NOG-ΔMHC mice were inoculated subcutaneously with 3.5 × 10⁶ U87MG EGFRvIII tumor cells on day 0 and then treated with intravenous injection of 1 × 10⁷ Conv. CAR-T, 7 × 19 CAR-T, or UTD on day 10. Thereafter, the tumor size (A) and the mouse survival (B) were assessed (n = 12 each in UTD and 7 × 19 CAR-T groups; n = 13 in Conv. CAR-T group; n values are biological replicates). In A, each line indicates the tumor volume of an individual mouse. Tumor volumes during the initial 56 days of 7 × 19 CAR-T–treated mice are shown in the inset. ***, P < 0.001.